BW Gestao de Investimentos Ltda. Purchases 112,595 Shares of Perrigo Company plc $PRGO

Key Points

• BW Gestao de Investimentos increased its Perrigo stake by 112,595 shares (7.7%)1.15% of Perrigo worth $35.23 million and making PRGO its ninth-largest position (1.5% of BW Gestao’s portfolio).
• Perrigo declared a quarterly dividend of $0.29 (annualized $1.16), representing a 11.2% yield; the ex-dividend date and record date are March 2, with payment on March 24.
• Recent results were mixed: quarterly EPS of $0.77 missed estimates of $0.80 while revenue of $1.11 billion slightly beat estimates but was down 2.5% year-over-year; management set FY2026 guidance of 2.25–2.55 EPS vs. analyst consensus of 2.56.

BW Gestao de Investimentos Ltda. boosted its position in shares of Perrigo Company plc (NYSE:PRGO - Free Report) by 7.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,582,119 shares of the company's stock after purchasing an additional 112,595 shares during the period. Perrigo makes up 1.5% of BW Gestao de Investimentos Ltda.'s portfolio, making the stock its 9th biggest position. BW Gestao de Investimentos Ltda. owned 1.15% of Perrigo worth $35,234,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PRGO. Geneos Wealth Management Inc. increased its position in shares of Perrigo by 439.1% during the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company's stock worth $27,000 after acquiring an additional 786 shares during the last quarter. Huntington National Bank boosted its holdings in Perrigo by 237.8% in the second quarter. Huntington National Bank now owns 1,054 shares of the company's stock valued at $28,000 after purchasing an additional 742 shares during the last quarter. Kestra Investment Management LLC grew its stake in Perrigo by 57.1% during the 2nd quarter. Kestra Investment Management LLC now owns 1,766 shares of the company's stock valued at $47,000 after purchasing an additional 642 shares in the last quarter. Jones Financial Companies Lllp grew its stake in Perrigo by 89.1% during the 3rd quarter. Jones Financial Companies Lllp now owns 1,778 shares of the company's stock valued at $38,000 after purchasing an additional 838 shares in the last quarter. Finally, Hantz Financial Services Inc. increased its holdings in Perrigo by 213.5% during the 3rd quarter. Hantz Financial Services Inc. now owns 3,869 shares of the company's stock worth $86,000 after purchasing an additional 2,635 shares during the last quarter. 95.91% of the stock is owned by hedge funds and other institutional investors.

Perrigo Price Performance

Shares of NYSE PRGO opened at $10.33 on Tuesday. The company has a current ratio of 2.76, a quick ratio of 1.63 and a debt-to-equity ratio of 1.23. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of -1.01, a price-to-earnings-growth ratio of 1.29 and a beta of 0.41. Perrigo Company plc has a twelve month low of $9.91 and a twelve month high of $29.08. The business has a 50 day simple moving average of $14.11 and a 200-day simple moving average of $16.90.

Perrigo (NYSE:PRGO - Get Free Report) last released its quarterly earnings data on Thursday, February 26th. The company reported $0.77 EPS for the quarter, missing analysts' consensus estimates of $0.80 by ($0.03). Perrigo had a positive return on equity of 9.41% and a negative net margin of 33.51%.The business had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.09 billion. During the same period in the prior year, the firm earned $0.93 EPS. The business's revenue for the quarter was down 2.5% compared to the same quarter last year. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. As a group, equities research analysts expect that Perrigo Company plc will post 2.56 earnings per share for the current year.

Perrigo Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 24th. Investors of record on Monday, March 2nd will be paid a dividend of $0.29 per share. This represents a $1.16 dividend on an annualized basis and a yield of 11.2%. The ex-dividend date is Monday, March 2nd. Perrigo's dividend payout ratio is presently -11.28%.

Analysts Set New Price Targets

Several research firms have recently commented on PRGO. Weiss Ratings reiterated a "sell (d+)" rating on shares of Perrigo in a research note on Monday, December 22nd. Argus upgraded shares of Perrigo to a "hold" rating in a research note on Wednesday, January 14th. Jefferies Financial Group reiterated a "hold" rating on shares of Perrigo in a research note on Thursday, February 26th. Canaccord Genuity Group decreased their price objective on shares of Perrigo from $20.00 to $17.00 and set a "buy" rating for the company in a report on Friday, February 27th. Finally, Zacks Research raised shares of Perrigo from a "strong sell" rating to a "hold" rating in a research report on Friday, February 13th. One investment analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $19.33.

Perrigo Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo's focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo's operations span research and development, manufacturing, quality assurance and global distribution.

Want to see what other hedge funds are holding PRGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Perrigo Company plc (NYSE:PRGO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.